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Abstract 
Background: Anti‑malarial drug resistance continues to be a leading threat to malaria control efforts and calls for 
continued monitoring of waning efficacy of artemisinin‑based combination therapy (ACT). Artesunate + sulfadoxine/
pyrimethamine (AS + SP) is used for the treatment of uncomplicated Plasmodium falciparum malaria in India. How‑
ever, resistance against AS + SP is emerged in northeastern states. Therefore, artemether–lumefantrine (AL) is the 
recommended first line treatment for falciparum malaria in north eastern states. This study investigates the therapeu‑
tic efficacy and safety of AL for the treatment of uncomplicated falciparum malaria in three malaria‑endemic states in 
India. The data generated through this study will benefit the immediate implementation of second‑line ACT as and 
when required.
Methods: This was a one‑arm prospective evaluation of clinical and parasitological responses for uncomplicated 
falciparum malaria using WHO protocol. Patients diagnosed with uncomplicated mono P. falciparum infection were 
administered six‑dose regimen of AL over 3 days and subsequent follow‑up was carried out up to 28 days. Molecu‑
lar markers msp‑1 and msp‑2 were used to differentiate recrudescence and re‑infection and K13 propeller gene was 
amplified and sequenced covering the codon 450–680.
Results: A total of 402 eligible patients were enrolled in the study from all four sites. Overall, adequate clinical and 
parasitological response (ACPR) was 98 % without PCR correction and 99 % with PCR correction. At three study sites, 
ACPR rates were 100 %, while at Bastar, cure rate was 92.5 % on day 28. No early treatment failure was found. The PCR‑
corrected endpoint finding confirmed that one late clinical failure (LCF) and two late parasitological failures (LPF) were 
recrudescences. The PCR corrected cure rate was 96.5 %. The mean fever clearance time was 27.2 h ± 8.2 (24–48 h) 
and the mean parasite clearance time was 30.1 h ± 11.0 (24–72 h). Additionally, no adverse event was recorded. 
Analysis of total 186 samples revealed a mutation in the k13 gene along with non‑synonymous mutation at codon 
M579T in three (1.6 %) samples.
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Background
Malaria is a major public health problem and a lead-
ing cause of mortality worldwide. The World Health 
Organization (WHO) estimated that 214 million cases 
of malaria occurred globally and approximately 438,000 
deaths were recorded in 2015 [1]. Globally, India is one 
of the 15 countries which accounted for 80 % of malaria 
cases and 78  % of malaria deaths in 2015 [1]. Approxi-
mately 91  % of India’s population lives in a malarious 
area, with 14 % of the population residing in a high-trans-
mission area [1]. Importantly, malaria is a major health 
problem in rural/tribal areas of central, eastern and north 
eastern states of India [2]. Plasmodium falciparum infec-
tion causes the most serious form of malaria and its 
proportion varies from 50 to 90  % in different states of 
the country. This study was undertaken in three out of 
five highly malarious states, i.e., Chhattisgarh, Madhya 
Pradesh and Jharkhand.
The emergence of P. falciparum resistance to chloro-
quine (CQ) and sulfadoxine–pyrimethamine (SP) has 
been a major obstacle to malaria control and is responsi-
ble for the spread across most parts of the country [3–5]. 
WHO has recommended artemisinin-based combination 
therapy (ACT) for the management of uncomplicated 
malaria cases. ACT reduces both malaria-related mor-
bidity and mortality and the transmission of P. falciparum 
by acting on gametocytes and reducing the chances of 
drug resistant development [6]. The National Drug Policy 
was revised in 2010 and since then AS + SP has become 
the first line for treatment of uncomplicated falcipa-
rum malaria in the country [7]. Recent studies revealed 
reduced AS + SP susceptibility, particularly in the north 
eastern states of India [8]; subsequently AS +  SP treat-
ment has been replaced with artemether–lumefantrine 
(AL) therapy in these areas as per revised National Drug 
Policy in the year 2013 [9].
AL is a co-formulation of artemether and lumefan-
trine (an aryl alcohol related to quinine, mefloquine and 
halofantrine) and is a commercially available fixed dose 
combination. In this combination, artemether, being a 
fast-acting drug, quickly reduces the parasite biomass 
[10] and resolves the clinical symptoms, while long-
acting lumefantrine prevents recrudescence. This dual 
effect eventually reduces the selective pressure on the 
parasite to develop resistance. AL has been available 
commercially in India since 2006 and is being used by the 
private sector [11]. Currently 40 countries in Africa and 
six countries in South America are using AL as their first- 
or second-line treatment [1].
Recently polymorphisms in the propeller region of P. 
falciparum Kelch protein (k13 gene) have been found to 
be associated with artemisinin resistance [12]. After this 
established association, WHO included k13 mutations in 
its new working definition for partial artemisinin resist-
ance [13]. In order to ensure effective malaria case man-
agement, it may be imperative to preserve the user life 
of ACT. WHO recommends a regular efficacy monitor-
ing by all malaria-endemic countries that have deployed 
ACT. One case of AL resistance was recorded in Odisha 
state, India [11].
The present study was conducted to evaluate the AL 
efficacy with six-dose regimen at four different sites in 
three states of India using the WHO therapeutic efficacy 
protocols. Based on these data, a second-line ACT will be 
available for implementation in the national programme 
as and when required.
Methods
Study design and sites
This was a one-arm prospective study conducted from 
October 2014 to August 2015. The study assessed clini-
cal and parasitological responses after AL administra-
tion to eligible patients. The primary endpoint was the 
28-day cure rate. This study was conducted at four Com-
munity Health Centres (CHCs) located in Anuppur and 
Jhabua districts of Madhya Pradesh, Simdega district of 
Jharkhand, and Bastar district of Chhattisgarh, which 
borders three states, i.e., Maharashtra, Odisha and 
Andhra Pradesh (Fig. 1). These sites were selected based 
on their malaria epidemiological and geographic profile. 
Plasmodium falciparum and Plasmodium vivax are the 
two dominant parasitic species with relative frequen-
cies of about 70 and 30  %, respectively, (although this 
value may vary according to location and season). The 
selected CHCs had sufficient facilities in terms of human 
resources and were well equipped with all required facili-
ties for management of uncomplicated malaria. All CHCs 
were situated near a secondary- or tertiary-level district 
hospital for referrals of severe malaria case management, 
if required.
Conclusion: AL is an efficacious drug for the treatment of uncomplicated falciparum malaria. However, regular 
monitoring of AL is required in view of malaria elimination initiatives, which will be largely dependent on therapeutic 
interventions, regular surveillance and targeted vector control.
Keywords: Therapeutic efficacy, Artemether–lumefantrine, Plasmodium falciparum, Malaria, India
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Study population
Consenting patients with uncomplicated falciparum 
malaria seeking care at the selected CHCs, who were aged 
6 months and above (>5 kg body weight), were enrolled 
in the study. Women in the age group 12–18 years were 
excluded as a request for a pregnancy test or initia-
tion of contraceptives is not acceptable within the local 
population.
Inclusion criteria
Symptomatic patients aged 6  months and above (>5  kg 
body weight) with uncomplicated malaria due to mono-
infection of P. falciparum (detected by microscopy at 
parasitaemia of 1000 to 100,000/μL asexual forms, axil-
lary temperature ≥37.5  °C) and willing to comply with 
the study protocol for the duration of the study were 
included [14].
Fig. 1 Map showing the study sites. District Jhabua and district Anuppur in Madhya Pradesh (MP); district Simdega in Jharkhand (JH); district Bastar 
in Chhattisgarh (CG) states
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Exclusion criteria
Patients with general danger signs or signs of severe fal-
ciparum malaria, who were unable to drink, had severe 
vomiting, reported a history of convulsion 7 days prior to 
patient contact, presence of lethargy or decreased con-
sciousness, inability to sit or stand, were all excluded. 
Patients who failed to complete treatment due to per-
sistent vomiting or failed to attend scheduled visits dur-
ing the first 3 days or withdrew their consent were also 
excluded [14].
Pregnancy test
Female patients of child-bearing age, defined as those 
who menstruate and are sexually active, were asked 
to take a urine pregnancy test before enrolment in the 
study, because the AL is contra-indicated during the first 
trimester of pregnancy. These patients were also asked to 
take a urine pregnancy test on the 28th day follow up for 
analysis purpose.
Procedures
After obtaining the informed written consent from 
patients or guardian, complete patient medical his-
tory (symptoms, current medications and previous use 
of anti-malarial drugs) was noted. A complete physi-
cal examination was performed and case record form 
was filled in for each patient. All enrolled patients were 
treated with AL on site, as directly observed treatment 
and monitored for 28 days [14]. Follow-ups were carried 
out on days 1, 2, 3, 7, 14, 21, and 28. On each follow-up, 
clinical signs and symptoms of malaria were recorded, 
blood smears were performed for detecting the malaria 
parasites, and filter-paper spot samples were taken for 
genotyping.
Anti‑malarial treatment
AL was obtained from the WHO Headquarter batch no. 
DYI573943, expiry date 09/2015 and administered by a 
Medical Officer based on the patient’s weight [6]. The day 
a patient was enrolled and received the first dose of AL 
was designated as ‘day 0’. A second dose was administered 
after 8  h and subsequent two doses daily was admin-
istered on the second and third day. Antimalarial was 
given with some food. Enrolled patients were observed 
for a minimum of 30 min after treatment to ensure that 
they did not vomit the drugs out. Patients with persis-
tent vomiting were excluded from the study and referred 
to the district hospital for appropriate management. 
Patients were advised not to take any herbal remedies 
during the study to avoid effects that would confound 
interpretation and lead to false results.
Microscopic blood examination
Parasite counts were done on Giemsa-stained thick films 
and the numbers of parasites per 200 white blood cells 
(WBCs) were counted by light microscopy. Parasite den-
sity, expressed as the number of asexual parasites per 
μL of blood, was calculated by dividing the number of 
asexual parasites by the number of WBCs counted, and 
then multiplying it by an assumed WBC density (typi-
cally 6000 per μL). When the number of asexual parasites 
was fewer than 100 per 200 WBCs in follow-up smears, 
counting was done against at least 500 WBCs. A blood-
slide sample was considered negative when examination 
of 1000 WBCs or 100 fields containing at least ten WBCs 
per field revealed no asexual parasites. The presence of 
gametocytes on the day the patient was enrolled or on 
the day of follow-up was also recorded.
Quality assurance of microscopy
Blood smears of enrolled patients, including follow-up 
smears, were examined by two independent microsco-
pists [one at each study site and another at the National 
Institute for Research in Tribal Health (NIRTH) Labo-
ratory, Jabalpur]. If any discordance was found, a third 
reading was performed by another senior microscopist. 
Quantification of parasitaemia was also performed by 
two independent microscopists with a third reading per-
formed by a senior microscopist if the difference between 
the first two readings varied by more than 25  %. Each 
reader was blinded to the result of other reader.
Polymerase chain reaction (PCR)
The PCR method was used to distinguish recrudescence 
from new infection in the case of treatment failure. 
Nested PCR was conducted to compare the genetic poly-
morphism of P. falciparum genes merozoite surface pro-
teins (msp1 and msp2) [3]. Recrudescence was defined as 
at least one identical allele for each of the two markers 
in the pre-treatment and post-treatment samples. New 
infections were diagnosed when all alleles for at least one 
of the markers differed between the two samples.
Follow‑up and loss to follow‑up
Parents or guardians of children were instructed to return 
to the health centre at any time if they had any general 
danger signs as described under exclusion criteria. The 
study team made home visits as follow-ups for study par-
ticipants that were late for their scheduled visits. Patients 
who failed to return on days 1 and 2 and missed one 
dose of the treatment or enrolled patients who could not 
attend scheduled visits were considered lost to follow-up 
(LFU) and excluded from the final analysis.
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Classification of responses to treatment
On the basis of parasitological and clinical outcome of 
treatment with AL, patients were classified according 
to the WHO definition of therapeutic responses: early 
treatment failure (ETF), late clinical failure (LCF), late 
parasitological failure (LPF) and adequate clinical and 
parasitological response (ACPR) [14].
k13 propeller gene amplification and sequencing
The k13 propeller gene was amplified by the nested PCR 
method described earlier by Ariey et  al. [12] with some 
modifications. The cycling conditions for the first round 
were as follows: an initial denaturation step at 94  °C for 
5 min; 35 cycles of denaturation at 94 °C for 30 s, anneal-
ing at 60 °C for 90 s and extension at 72 °C for 90 s; fol-
lowed by a final extension at 72 °C for 10 min. The cycling 
conditions for the second round were same as first round 
for 30 cycles. All amplification reactions were carried out 
in a final volume of 25 μL. An aliquot of the PCR prod-
ucts was analysed by electrophoresis on a 1.5 % agarose 
gel stained with ethidium bromide to confirm amplifi-
cation. The capillary sequencing of 849  bp (1279–2127) 
PCR products was performed by means of Sanger 
sequencer standard methods, using the Applied Biosys-
tems 3130XL system. The sequences were analysed using 
software Bioedit Sequence Alignment Editor v. 7.0.5.2 
and aligned with sequences of PF3D7 1343700 Kelch pro-
tein propeller domain using the online sequence align-
ment tool ClustalW. The nucleotide sequence of k13 gene 
of P. falciparum isolate from the study site has been sub-
mitted to GenBank under Accession number KX121048, 
KX121049.
Data analysis
Data from both clinical and parasitological assessments 
for each participant were entered into the WHO stand-
ardized Microsoft Excel data collection sheet. This form 
was used for both data management and analysis. All data 
were independently entered double blind. Data were ana-
lysed by estimation of difference in proportion accord-
ing to a 95 % confidence interval. Groups were compared 
using Chi Square test or Fisher Exact test for categorical 
variables and Student’s t test for continuous variables 
where ever applicable. Otherwise, non-parametric tests 
(Mann–Whitney, Kruskal–Wallis) were used.
Results
Characteristics of the study population
A total of 402 eligible patients (61  % males and 39  % 
females) were enrolled in the study from all four sites and 
the baseline demographics are presented in Table 1. The 
highest number of patients (228, 57 %) was from the age 
group of 5–15 years, while 128 patients (32 %) were older 
children and adults (age >15  years), with the age group 
under 5 years representing the lowest number of patients 
(46.11  %). The mean age of the study population was 
highest from Anuppur at 21 years ± 18.5 (0.8–60 years) 
and lowest from Jhabua at 12 years ± 11.3 (1–58 years). 
The mean body weight was almost the same from all 
sites (mean body weight range: 27–30 kg). The geometric 
mean of parasite density was relatively higher at 7868.93/
μL (95  % CI 6430.46–9629.19) in Bastar and lowest at 
2518.11/μL in Anuppur (95 % CI 2015.28–3146.39).
Therapeutic efficacy
Among a total of 402 patients (see Additional file 1), 24 
patients were lost to follow-up because of high popula-
tion movement in connection with wage earning and 
could not be traced; 42 patients withdrew from the study 
mainly as they were not taken complete treatment. Out 
of the remaining 336 subjects, three (0.89  %; 95  % CI 
0.18–2.50) patients were recorded as LCF (one on day 
21 and two on day 28), four (1.19 %; 95 % CI 0.32–3.02) 
patients as LPF (all on day 28) and the remaining 329 
(97.92 %; 95 % CI 95.75–99.16) patients were classified as 
ACPR (Table 2). There were no ETF and the clinical cure 
rate was 98 %. All four cases of LPF and two cases of LCF 
were in the age-group of 5–15 years whereas the sole case 
LCF was an adult patient. All these LCF and LPF cases 
were reported from Bastar, Chhattisgarh. No adverse 
event was recorded. Participants with treatment failure 
were given an alternative treatment of AS  +  SP as per 
national guideline. The PCR corrected endpoint findings 
confirmed one LCF (7 years) and two LPF (both 6 years) 
patients having P. falciparum recrudescence, while the 
remaining two LCF and one LPF patients were con-
firmed as having P. falciparum re-infection with one LPF 
shown as PCR negative. The PCR-corrected cure rate by 
Kaplan–Meier analysis at Bastar was 96.5  %. Merozoite 
surface protein 1 (Pfmsp 1) and merozoite surface protein 
2 (Pfmsp 2) genotyping was performed for all the treat-
ment failure samples on day 0 and day of failure. Out of 
the seven cases, six were found positive for P. falciparum 
on both days (day 0 and day of failure). Two cases were 
recrudescence (same allele for msp1 and msp2) whereas 
three patients having re-infection at the time of treat-
ment failure. However, one patient had mixed msp2 allele 
at the time of treatment failure.
Fever, parasite and gametocyte clearance
At the time of enrolment, 63 % of the patients had fever. 
The mean fever clearance time was 27.2  h  ±  8.2 (24–
48  h) (Table  2). For all study subjects, fever subsided 
within 2  days. The mean parasite clearance time was 
30.1 h ± 11.0 (24–72 h). By day 3, all study subjects were 
cleared for asexual parasites. Gametocytes were detected 
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in 6.7 % (n =  27) of the patients on day 0 and all these 
patients cleared gametocytes by day 14.
Plasmodium falciparum k13‑propeller mutation
A total of 243 samples were used to analyse the muta-
tion in k13 gene. Out of 243 samples, sequencing of 
the propeller region of k13 gene was done in 186 iso-
lates (Table  3). After alignment with PF3D7 1343700, 
non-synonymous mutations (NS) were found in three 
(1.6 %) samples at codon M579T while the rest of the 183 
sequences were perfectly aligned (codons 450–680) with 
wild type. All three samples were from the state of Mad-
hya Pradesh. Treatment responses were good in each of 
the three patients harbouring NS k13 mutations.
Discussion
This study was carried out in three states (Chhattisgarh, 
Madhya Pradesh and Jharkhand), which are classified as 
the second, third and fourth highest malarious states, due 
to their high contribution in total malaria cases (11.0, 
8.6 and 8.01 %, respectively) within the country [2]. The 
present ACT (AS  +  SP) recommended by the national 
programme is highly effective in most parts of the coun-
try, but available as a blister pack and not a fixed dose 
formulation. AL is the fixed dose combination that has 
been approved for marketing. This study has demon-
strated that overall AL is highly effective for the treat-
ment of uncomplicated falciparum malaria in all ages 
and in areas prone to high malaria transmission. Clinical 











 Mean 12.12 21.03 14.72 17.02 16.01
 sd 11.34 18.55 11.52 15.81 14.61
 Min 1 0.83 2 2 0.83
 Max 58 60 49 60 60
Age group (years) (%)
 Under 5 16 (16.23) 10 (11.24) 11 (8.94) 9 (9.78) 46 (11.44)
 5–15 59 (60.20) 42 (47.19) 72 (58.54) 55 (59.78) 228 (56.72)
 Adult 23 (23.47) 37 (41.57) 40 (32.52) 28 (30.43) 128 (31.84)
Sex
 Male (%) 67 (68.37) 47 (52.81) 80 (65.04) 53 (57.61) 247 (61.44)
 Female (%) 31 (31.63) 42 (47.19) 43 (34.96) 39 (42.39) 155 (38.56)
Weight (kg)
 Mean 26.84 30.2 30.7 28.06 29.04
 sd 13.66 15.82 15.88 14.73 15.10
 Min 8 5 9 9 5
 Max 67 64 64 65 67
Height (cm)
 Mean 127.98 133.98 132.36 130 131.11
 sd 26.33 26.16 27.59 25.51 26.47
 Min 37 65 60 65 37
 Max 175 173 170 168.9 175
Parasite density/µL (at enrollment)
 Geometric mean 6868.41 2518.11 7868.93 3031.62 4750.77
 95 % CI (5755.9–8195.9) (2015.3–3146.4) (6430.5–9629.2) (2086.4–4405.1) (4163.18–5421.30)
 <2000/µL n (%) 9 (9.2) 45 (50.6) 15 (12.2) 22 (23.9) 91 (22.64)
 >2000/µL n (%) 30 (30.6) 27 (30.3) 29 (23.6) 33 (35.9) 119 (29.60)
 >5000/µL n (%) 28 (28.6) 6 (6.7) 27 (21.9) 16 (17.4) 77 (19.15)
 >10,000/µL n (%) 31 (31.6) 11 (12.4) 52 (42.3) 21 (22.8) 115 (28.61)
Gametocyte carriage
 n (%) 7 (7.1) 10 (11.2) 2 (1.6) 8 (8.7) 27 (6.72)
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improvement with AL was swift with rapid fever clear-
ance. Gametocytic clearance was observed in all 27 par-
ticipants by the fourteenth day with all of them becoming 
gametocyte-free by day 28, similar to the previous report 
[15]. The aggregated mean cure rate was 98  % without 
PCR correction and 99  % with PCR correction. This 
finding is consistent with the therapeutic efficacy val-
ues reported worldwide, including India [11, 15–17]. In 
Ethiopia, AL remains highly effective in the treatment of 
uncomplicated falciparum malaria and reduced gameto-
cyte carriage even 8 years after its introduction [18].
In this study, three cases of treatment failure on day 
21 and day 28 were young children. It is not known 
whether this is due to actual resistance of parasites to 
drugs or due to inadequate blood levels caused by poor 
drug absorption or altered pharmacokinetics. The study 
has limitation as the characterization the recrudescence 
vs. re-infection is based on only two population marker 
gene (msp1 and msp2) and not all the three marker genes 
(msp, msp2 and Pfglurp). All three cases of treatment fail-
ure were from Bastar, a highly malarious district border-
ing Odisha state, which contributes the highest number 
Table 2 Treatment outcomes by day 28, fever and parasite clearance times with AL by study site
Variables Study sites Total
Jhabua (MP) Anuppur (MP) Bastar (CG) Simdega (JH)
PCR unadjusted
 Early treatment failure 0 0 0 0 0
 Late clinical failure 0 0 3 0 3
 Late parasitological failure 0 0 4 0 4
 Adequate clinical and parasitological response (%) 80 (100 %) 75 (100) 86 (92.5) 88 (100) 329 (97.9)
PCR adjusted
 Early treatment failure 0 0 0 0 0
 Late clinical failure 0 0 1 0 1
 Late parasitological failure 0 0 2 0 2
 Adequate clinical and parasitological response (%) 80 75 86 (95.6) 88 (100) 329 (99.1)
 Pf recrudescence 0 0 2 0 2
 Pf re‑infection 0 0 3 0 3
 Mixed with Pf recrudescence 0 0 1 0 1
 PCR negative (unknown) 0 0 1 0 1
Fever clearance time (hours)
 Mean 27.4 24.0 26.1 28.8 27.7
 sd 8.4 0.0 6.8 9.7 8.1
 Min 24 24 24 24 24
 Max 48 24 48 48 48
Parasite clearance time (hours)
 Mean 25.5 31.3 32.9 30.0 30.1
 sd 5.8 12.7 12.1 10.5 10.9
 Min 24 24 24 24 24
 Max 48 48 72 48 72
Table 3 Distribution of samples and non-synonymous mutations




Chhattisgarh Bastar 93 79 (85) 0 (0.0)
Madhya Pradesh Anuppur 50 32 (64.0) 1 (3.1)
Jhabua 50 38 (76.0) 2 (5.2)
Jharkhand Jaldega 50 37 (74.0) 0 (0.0)
Total 243 186 (74.4) 3 (1.6)
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of malaria cases and malarial deaths in the country [2]. It 
is worthwhile to mention that the first case of AL resist-
ance was also found in Odisha [11]. Studies carried out 
in a tertiary hospital in Bastar revealed that P. falciparum 
causes cerebral and severe malaria with a case fatality 
rate of 32 and 9 %, respectively, in PCR-confirmed mono 
P. falciparum among hospitalized patients [19]. Since fal-
ciparum malaria was significantly more prevalent in chil-
dren than adults, the recrudescence of parasites on days 
21 and 28 in this district led to investigate possible drug 
misuse, since AL was distributed without prescription by 
local chemists. Free availability of drugs and its misuse 
raises concerns of developing drug resistance in this area, 
where malnourished tribal people constitute more than 
70 % of the population and where the P. falciparum pro-
portion is more than 85 % [19]. As malnutrition and poor 
uptake of fat is common in poverty-stricken tribal popu-
lations, care should be taken to prescribe drugs with fatty 
food to ensure good absorption.
In the present study, NS gene among three isolates was 
detected in the highly conserved K13 propeller gene of 
P. falciparum parasites. As definite phenotype of ACT 
resistance is very rare, the association of polymorphism 
in marker genes is very difficult to correlate with the effi-
cacy outcome. Ariey et  al. have reported that polymor-
phisms C580Y, Y493H and R539T in the propeller region 
of k13 gene are strongly associated with artemisinin 
resistance [12]. Following this discovery, several research-
ers reported a number of single nucleotide polymor-
phism (SNPs) in this gene, particularly at the propeller 
region, from different parts of the world [20–26]. Three 
samples from this study showed mutation at M579T 
codon, which is not directly linked with resistance but is 
located adjacent to the C580Y mutation responsible for 
delayed parasite clearance [12]. No mutation was found 
in the propeller part of the gene among the three cases 
that were treatment failure (LCF and LPF). However, ear-
lier studies carried out in India did not find C580Y SNP 
in the P. falciparum k13 propeller gene [21, 27].
Conclusion
The high cure rate and parasite clearance time in this 
study indicate no imminent threat to artemisinin resist-
ance in the regions investigated. As artemisinin deriva-
tives rapidly reduce the symptoms with an additional 
advantage of anti gametocidal activity to reduce malaria 
transmission [28]. However, regular monitoring of anti-
malaria efficacy is required to satisfy the objectives of 
the malaria elimination initiative programmes, which are 
largely based on therapeutic interventions, regular sur-
veillance and targeted vector control. Finally, it is impor-
tant to conduct detailed phenotyping and genotyping 
studies for determining artemisinin resistance in such 
high malarious regions of India.
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